141 related articles for article (PubMed ID: 2497064)
1. Fluctuations of plasma beta 2-microglobulin, soluble interleukin 2 receptor and interferon-gamma concentrations after adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
Giannella G; Pelosi-Testa E; Carlini P; Habetswallner D; Montesoro E; Camagna A; Calzini V; Ruggeri EM; Arena MG; Masciulli R
Immunobiology; 1989 Feb; 178(4-5):305-15. PubMed ID: 2497064
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 2-activated killer cells: generation in collaboration with interferon gamma and its suppression in cancer patients.
Shiiba K; Suzuki R; Kawakami K; Ohuchi A; Kumagai K
Cancer Immunol Immunother; 1986; 21(2):119-28. PubMed ID: 3081248
[TBL] [Abstract][Full Text] [Related]
3. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
4. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Belli F; Sciorelli G; Ravagnani F; Galazka AR; Cascinelli N; Parmiani G
Cancer Res; 1989 Sep; 49(18):5230-4. PubMed ID: 2788498
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral rIL2-based immunotherapy in B16 melanoma.
Yeung RS; Vollmer C; Taylor DD; Palazzo J; Weese JL
J Surg Res; 1992 Aug; 53(2):203-10. PubMed ID: 1405610
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
7. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.
Lotze MT; Rosenberg SA
Immunobiology; 1986 Sep; 172(3-5):420-37. PubMed ID: 3100435
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
10. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
Taguchi T; Domoto K
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.
Shimizu K; Okamoto Y; Miyao Y; Yamada M; Ushio Y; Hayakawa T; Ikeda H; Mogami H
J Neurosurg; 1987 Apr; 66(4):519-21. PubMed ID: 3494108
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment.
Boccoli G; Masciulli R; Ruggeri EM; Carlini P; Giannella G; Montesoro E; Mastroberardino G; Isacchi G; Testa U; Calabresi F
Cancer Res; 1990 Sep; 50(18):5795-800. PubMed ID: 2118421
[TBL] [Abstract][Full Text] [Related]
13. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
Topalian SL; Rosenberg SA
Acta Haematol; 1987; 78 Suppl 1():75-6. PubMed ID: 3124451
[TBL] [Abstract][Full Text] [Related]
14. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Rosenberg SA
Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
[No Abstract] [Full Text] [Related]
16. Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique.
Favrot MC; Coze C; Combaret V; Gaspard M; Colin C; Franks C; Negrier S; Philip I; Philip T
Mol Biother; 1990 Mar; 2(1):32-7. PubMed ID: 2185792
[TBL] [Abstract][Full Text] [Related]
17. [LAK cells and cancer].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
[TBL] [Abstract][Full Text] [Related]
18. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
[No Abstract] [Full Text] [Related]
19. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
20. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
